Finance

Lists
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
၃၀၁.၇၉ US$
+၁.၂၇%
(+၃.၇၉) 1D
၃၀၁.၇၉ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၅  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
၂၉၄.၆၀ US$
High
၃၀၅.၂၀ US$
Low
၂၉၄.၆၀ US$
Mkt. cap
ဋေ ၁.၄၄ ထ
Avg. vol.
၉.၈၂ သိန်း
Volume
၆.၈၀ သိန်း
52-wk high
၃၃၃.၃၀ US$
52-wk low
၁၄၆.၂၀ US$
EPS
-၄.၈၅ US$
Beta
၁.၄၀
Shares outstanding
၄.၇၇ ကုဋေ
No. of employees
၂ သောင်း
Open
၂၉၄.၆၀ US$
High
၃၀၅.၂၀ US$
Low
၂၉၄.၆၀ US$
Mkt. cap
ဋေ ၁.၄၄ ထ
Avg. vol.
၉.၈၂ သိန်း
Volume
၆.၈၀ သိန်း
52-wk high
၃၃၃.၃၀ US$
52-wk low
၁၄၆.၂၀ US$
EPS
-၄.၈၅ US$
Beta
၁.၄၀
Shares outstanding
၄.၇၇ ကုဋေ
No. of employees
၂ သောင်း
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ ရက်
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၃ ရက်
Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees၁.၉ သောင်း
Founded၁၉၄၇
HeadquartersWilmington, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitecriver.com
Analyst ratings
Based on 16 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
2
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current ၃၀၁.၇၉ US$
၃၅၇.၀၀ US$ (+၁၈.၂၉%)
Average
၃၁၆.၅၇ US$ (+၄.၉၀%)
Lowest
၂၁၉.၀၀ US$ (-၂၇.၄၃%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Halsted
RBC Capital
Buy
Maintained
၃၂၂.၀၀ US$
+၆.၇%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
၃၅၇.၀၀ US$
+၁၈.၃%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
၃၄၀.၀၀ US$
+၁၂.၇%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
၃၂၀.၀၀ US$
+၆%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
၃၃၀.၀၀ US$
+၉.၃%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
၂၉၅.၀၀ US$
-၂.၂%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
၃၃၄.၀၀ US$
+၁၀.၇%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
၃၃၀.၀၀ US$
+၉.၃%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
၃၂၅.၀၀ US$
+၇.၇%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
၃၂၀.၀၀ US$
+၆%
09/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
၃၀၀.၀၀ US$
-၀.၆%
09/21/2026
David Toung
Argus Research
Buy
Reiterated
၃၃၀.၀၀ US$
+၉.၃%
09/16/2026
Casey Woodring
J.P. Morgan
Buy
Upgraded
၃၁၀.၀၀ US$
+၂.၇%
08/05/2026
Michael Luo CFA
CLSA
Hold
Downgraded
၂၁၉.၀၀ US$
-၂၇.၄%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
၂၆၅.၀၀ US$
-၁၂.၂%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
၂၁၅.၀၀ US$
-၂၈.၈%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
၁၇၅.၀၀ US$
-၄၂%
02/25/2026
Last report
၂၀၂၆ ဩ ၅
Fiscal period
Q2 2026
၃.၀၂ US$ / ၂.၇၄ US$
+၁၀.၃၁%beat
Revenue / Est. (USD)
၁၀၀.၄၁ ဋေ / ၉၇.၇၂ ကုဋေ
+၂.၇၅%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၁၀၀.၄၉ ဋေ
၉၉.၄၂ ကုဋေ
၉၉.၅၈ ကုဋေ
၁၀၀.၄၁ ဋေ
Cost of goods sold
၆၅.၂၇ ကုဋေ
၆၆.၅၄ ကုဋေ
၆၇.၂၈ ကုဋေ
၆၂.၅၁ ကုဋေ
Cost of revenue
၆၅.၂၇ ကုဋေ
၆၆.၅၄ ကုဋေ
၆၇.၂၈ ကုဋေ
၆၂.၅၁ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၇.၃၆ ကုဋေ
၁၉.၂၀ ကုဋေ
၁၄.၉၁ ကုဋေ
၂၁.၄၂ ကုဋေ
Operating expense
၂၀.၁၀ ကုဋေ
၂၈.၄၀ ကုဋေ
၁၆.၄၅ ကုဋေ
၂၂.၇၃ ကုဋေ
Total operating expenses
၈၅.၃၈ ကုဋေ
၉၄.၉၄ ကုဋေ
၈၃.၇၃ ကုဋေ
၈၅.၂၃ ကုဋေ
Operating income
၁၅.၁၁ ကုဋေ
၄.၄၈ ကုဋေ
၁၅.၈၆ ကုဋေ
၁၅.၁၇ ကုဋေ
Other non operating income
-၂.၂၆ ကုဋေ
၂.၇၇ ကုဋေ
-၁၂.၃၁ ကုဋေ
၂.၆၀ ကုဋေ
EBT including unusual items
၈.၇၂ ကုဋေ
-၂၉.၄၁ ကုဋေ
-၂.၉၉ ကုဋေ
၅.၃၂ ကုဋေ
EBT excluding unusual items
၁၀.၄၅ ကုဋေ
၃.၅၂ ကုဋေ
၈.၆၂ သန်း
၁၄.၈၄ ကုဋေ
Income tax expense
၃.၁၆ ကုဋေ
-၁.၇၈ ကုဋေ
-၁.၅၁ ကုဋေ
၅.၃၉ ကုဋေ
Effective tax rate
၃၆.၂၉%
၆.၀၆%
၅၀.၅၆%
၁၀၁.၄၃%
Other operating expenses
-
-
-
-
Net income
၅.၄၄ ကုဋေ
-၂၇.၆၆ ကုဋေ
-၁.၄၈ ကုဋေ
-၁.၄၈ သန်း
Net profit margin
၅.၄၂%
-၂၇.၈၂%
-၁.၄၉%
-၀.၁၅%
Earnings per share
၂.၄၃
၂.၃၉
၂.၀၆
၃.၀၂
Interest and investment income
၁.၄၂ သန်း
၁.၀၂ သန်း
၁.၀၃ သန်း
၁.၀၃ သန်း
Interest expense
-၂.၅၄ ကုဋေ
-၂.၃၈ ကုဋေ
-၂.၆၇ ကုဋေ
-၃.၀၃ ကုဋေ
Net interest expenses
-၂.၄၀ ကုဋေ
-၂.၂၈ ကုဋေ
-၂.၅၇ ကုဋေ
-၂.၉၃ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၂၃.၆၂ ကုဋေ
၁၆.၉၆ ကုဋေ
၂၂.၅၇ ကုဋေ
၂၁.၇၅ ကုဋေ
Gain or loss from assets sale
-
-
၁၁.၈၀ ကုဋေ
၂.၄၉ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ